TN2015000285A1 - Therapeutically active pyrazolo-pyrimidine derivatives - Google Patents

Therapeutically active pyrazolo-pyrimidine derivatives

Info

Publication number: TN2015000285A1
Authority: TN; Tunisia
Prior art keywords: pyrimidine derivatives; therapeutically active; pyrazolo; active pyrazolo; diseasesand
Prior art date: 2012-12-20

Application number

TNP2015000285A

Other languages

English (en)

Inventor

Daniel James Ford

Richard Jeremy Franklin

Anant Ramrao Ghawalkar

Helen Tracey Horsley

Qiuya Huang

James Thomas Reuberson

Bart Vanderhoydonck

Original Assignee

Ucb Biopharma Sprl

Univ Leuven Kath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-20

Filing date

2015-06-18

Publication date

2016-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-20 Priority claimed from GBGB1223021.5A external-priority patent/GB201223021D0/en

2013-02-04 Priority claimed from GBGB1301935.1A external-priority patent/GB201301935D0/en

2015-06-18 Application filed by Ucb Biopharma Sprl, Univ Leuven Kath filed Critical Ucb Biopharma Sprl

2016-10-03 Publication of TN2015000285A1 publication Critical patent/TN2015000285A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)

TNP2015000285A 2012-12-20 2015-06-18 Therapeutically active pyrazolo-pyrimidine derivatives TN2015000285A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1223021.5A GB201223021D0 (en)	2012-12-20	2012-12-20	Therapeutic agents
GBGB1301935.1A GB201301935D0 (en)	2013-02-04	2013-02-04	Therapeutic agents
PCT/EP2013/077846 WO2014096423A1 (fr)	2012-12-20	2013-12-20	Dérivés de pyrazolo-pyrimidine thérapeutiquement actifs

Publications (1)

Publication Number	Publication Date
TN2015000285A1 true TN2015000285A1 (en)	2016-10-03

Family

ID=49886937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000285A TN2015000285A1 (en)	2012-12-20	2015-06-18	Therapeutically active pyrazolo-pyrimidine derivatives

Country Status (32)

Country	Link
US (1)	US9714248B2 (fr)
EP (1)	EP2935269B1 (fr)
JP (1)	JP6298830B2 (fr)
KR (1)	KR102215490B1 (fr)
CN (1)	CN105008360B (fr)
AP (1)	AP2015008552A0 (fr)
AU (1)	AU2013366480B2 (fr)
BR (1)	BR112015014869A2 (fr)
CA (1)	CA2893704C (fr)
CL (1)	CL2015001752A1 (fr)
CR (1)	CR20150379A (fr)
CY (1)	CY1120415T1 (fr)
DK (1)	DK2935269T3 (fr)
EA (1)	EA027752B1 (fr)
ES (1)	ES2676515T3 (fr)
HR (1)	HRP20181008T1 (fr)
HU (1)	HUE038310T2 (fr)
IL (1)	IL239163B (fr)
LT (1)	LT2935269T (fr)
MX (1)	MX376436B (fr)
MY (1)	MY189182A (fr)
NZ (1)	NZ709360A (fr)
PE (1)	PE20151767A1 (fr)
PH (1)	PH12015501222B1 (fr)
PL (1)	PL2935269T3 (fr)
PT (1)	PT2935269T (fr)
SA (1)	SA515360627B1 (fr)
SG (2)	SG11201504291SA (fr)
SI (1)	SI2935269T1 (fr)
TN (1)	TN2015000285A1 (fr)
TR (1)	TR201809140T4 (fr)
WO (1)	WO2014096423A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201410815D0 (en)	2014-06-17	2014-07-30	Ucb Biopharma Sprl And Katholieke Universiteit Leuven	Therapeutic agents
GB201517264D0 (en) *	2015-09-30	2015-11-11	Ucb Biopharma Sprl And Katholieke Universiteit Leuven	Therapeutic agents
GB201517263D0 (en) *	2015-09-30	2015-11-11	Ucb Biopharma Sprl And Katholieke Universiteit Leuven	Therapeutic agents
GB201521767D0 (en)	2015-12-10	2016-01-27	Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D	Therapeutic agents
MY197171A (en)	2017-03-20	2023-05-28	Broad Inst Inc	Compounds and methods for the treatment of parasitic diseases
CN109721531B (zh) *	2017-10-27	2022-07-29	中国科学院合肥物质科学研究院	一种新型的脂质体激酶抑制剂
UY38051A (es)	2018-01-17	2019-08-30	Glaxosmithkline Ip Dev Ltd	INHIBIDORES DE LA PI4KIIIß
CN112752761B (zh)	2018-08-21	2024-03-29	杏林制药株式会社	双环杂芳族环衍生物
US20230212172A1 (en) *	2020-06-08	2023-07-06	University Of Vermont And State Agricultural College	Arylacetamide analogs of piperazine-[1,2,4]triazolo[4,3-b]pyridazines
KR102673131B1 (ko) *	2020-07-28	2024-06-10	아주대학교산학협력단	신규한 톨-유사 수용체 3/7/9 억제 소분자 화합물
WO2024168104A2 (fr) *	2023-02-09	2024-08-15	Caraway Therapeutics, Inc.	Modulateurs de trpml, leurs compositions et procédés d'utilisation
WO2024168106A2 (fr) *	2023-02-09	2024-08-15	Caraway Therapeutics, Inc.	Modulateurs de trpml, leurs compositions et procédés d'utilisation
CN116444485B (zh) *	2023-03-30	2024-01-23	广西中医药大学	吡啶基取代不对称脲的非金属催化、免柱层析合成方法
WO2024211249A2 (fr) *	2023-04-05	2024-10-10	Caraway Therapeutics, Inc.	Modulateurs de trpml, leurs compositions et procédés d'utilisation
WO2024249604A2 (fr) *	2023-06-02	2024-12-05	Purdue Research Foundation	Inhibiteurs covalents utilisés en tant qu'agents antipaludiques
EP4623912A1 (fr)	2024-03-25	2025-10-01	ETH Zurich	Procédé de dégonflage d'une foie stéatotique ex vivo
EP4623911A1 (fr)	2024-03-25	2025-10-01	ETH Zurich	Inhibiteurs de pi4kb pour le traitement de la stéatose hépatique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1110649B (de) *	1957-11-22	1961-07-13	Ciba Geigy	Verfahren zur Herstellung von 1-Isopropyl-pyrazolo[3, 4-d]pyrimidinen
EP1067123B1 (fr) *	1998-03-31	2011-01-19	Kyowa Hakko Kirin Co., Ltd.	Composes heterocycliques azotes
TWI259083B (en) *	2002-05-24	2006-08-01	Nat Health Research Institutes	Anti-enterovirus compounds
US8362264B2 (en) *	2003-08-22	2013-01-29	Dendreon Corporation	Compositions and methods for the treatment of disease associated with Trp-p8 expression
JP5213229B2 (ja) *	2004-04-23	2013-06-19	エグゼリクシス，インコーポレイテッド	キナーゼ調節因子および使用方法
WO2006009245A1 (fr) *	2004-07-23	2006-01-26	Tanabe Seiyaku Co., Ltd.	Composé bicyclique azoté
JP5274842B2 (ja) *	2004-12-28	2013-08-28	エグゼリクシス，インコーポレイテッド	免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
CN101981037B (zh) *	2008-01-30	2013-09-04	吉宁特有限公司	吡唑并嘧啶pi3k抑制剂化合物及使用方法
EP2923734B1 (fr) *	2009-03-13	2018-01-10	Katholieke Universiteit Leuven, K.U. Leuven R&D	Analogues de purines et leur utilisation en tant qu'agents immunosuppresseurs
WO2010118367A2 (fr) *	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Pyrimidines antivirales

2013
- 2013-12-20 AP AP2015008552A patent/AP2015008552A0/xx unknown
- 2013-12-20 HU HUE13814962A patent/HUE038310T2/hu unknown
- 2013-12-20 SG SG11201504291SA patent/SG11201504291SA/en unknown
- 2013-12-20 CN CN201380066813.4A patent/CN105008360B/zh not_active Expired - Fee Related
- 2013-12-20 WO PCT/EP2013/077846 patent/WO2014096423A1/fr not_active Ceased
- 2013-12-20 NZ NZ709360A patent/NZ709360A/en not_active IP Right Cessation
- 2013-12-20 AU AU2013366480A patent/AU2013366480B2/en not_active Ceased
- 2013-12-20 HR HRP20181008TT patent/HRP20181008T1/hr unknown
- 2013-12-20 MX MX2015007774A patent/MX376436B/es active IP Right Grant
- 2013-12-20 SG SG10201703094UA patent/SG10201703094UA/en unknown
- 2013-12-20 LT LTEP13814962.0T patent/LT2935269T/lt unknown
- 2013-12-20 PT PT138149620T patent/PT2935269T/pt unknown
- 2013-12-20 SI SI201331080T patent/SI2935269T1/sl unknown
- 2013-12-20 EP EP13814962.0A patent/EP2935269B1/fr active Active
- 2013-12-20 TR TR2018/09140T patent/TR201809140T4/tr unknown
- 2013-12-20 BR BR112015014869A patent/BR112015014869A2/pt not_active Application Discontinuation
- 2013-12-20 PL PL13814962T patent/PL2935269T3/pl unknown
- 2013-12-20 MY MYPI2015701917A patent/MY189182A/en unknown
- 2013-12-20 KR KR1020157018482A patent/KR102215490B1/ko not_active Expired - Fee Related
- 2013-12-20 EA EA201500654A patent/EA027752B1/ru not_active IP Right Cessation
- 2013-12-20 JP JP2015548662A patent/JP6298830B2/ja not_active Expired - Fee Related
- 2013-12-20 US US14/650,771 patent/US9714248B2/en not_active Ceased
- 2013-12-20 DK DK13814962.0T patent/DK2935269T3/en active
- 2013-12-20 ES ES13814962.0T patent/ES2676515T3/es active Active
- 2013-12-20 CA CA2893704A patent/CA2893704C/fr active Active
- 2013-12-20 PE PE2015001053A patent/PE20151767A1/es unknown
2015
- 2015-06-01 PH PH12015501222A patent/PH12015501222B1/en unknown
- 2015-06-03 IL IL239163A patent/IL239163B/en active IP Right Grant
- 2015-06-18 TN TNP2015000285A patent/TN2015000285A1/fr unknown
- 2015-06-18 CL CL2015001752A patent/CL2015001752A1/es unknown
- 2015-06-18 SA SA515360627A patent/SA515360627B1/ar unknown
- 2015-07-17 CR CR20150379A patent/CR20150379A/es unknown
2018
- 2018-07-11 CY CY20181100728T patent/CY1120415T1/el unknown

Also Published As

Publication number	Publication date
AU2013366480B2 (en)	2017-06-22
EP2935269A1 (fr)	2015-10-28
CA2893704A1 (fr)	2014-06-26
NZ709360A (en)	2020-01-31
BR112015014869A2 (pt)	2017-07-11
SG11201504291SA (en)	2015-07-30
WO2014096423A1 (fr)	2014-06-26
HK1215705A1 (en)	2016-09-09
PH12015501222A1 (en)	2015-08-17
EA027752B1 (ru)	2017-08-31
KR20150111348A (ko)	2015-10-05
DK2935269T3 (en)	2018-07-16
CN105008360B (zh)	2017-09-19
IL239163A0 (en)	2015-07-30
KR102215490B1 (ko)	2021-02-15
CN105008360A (zh)	2015-10-28
SG10201703094UA (en)	2017-06-29
PE20151767A1 (es)	2015-12-11
MX2015007774A (es)	2015-09-04
SI2935269T1 (sl)	2018-09-28
PT2935269T (pt)	2018-07-16
CY1120415T1 (el)	2019-07-10
CA2893704C (fr)	2020-12-15
PL2935269T3 (pl)	2018-09-28
EA201500654A1 (ru)	2015-12-30
US20160194329A1 (en)	2016-07-07
US9714248B2 (en)	2017-07-25
ES2676515T3 (es)	2018-07-20
CL2015001752A1 (es)	2016-06-03
JP2016503049A (ja)	2016-02-01
LT2935269T (lt)	2018-07-10
IL239163B (en)	2018-06-28
HRP20181008T1 (hr)	2018-08-24
TR201809140T4 (tr)	2018-07-23
HUE038310T2 (hu)	2018-10-29
AU2013366480A1 (en)	2015-07-09
SA515360627B1 (ar)	2018-05-31
PH12015501222B1 (en)	2015-08-17
CR20150379A (es)	2015-10-08
MY189182A (en)	2022-01-31
JP6298830B2 (ja)	2018-03-20
MX376436B (es)	2025-03-07
AP2015008552A0 (en)	2015-06-30
EP2935269B1 (fr)	2018-04-11

Publication	Publication Date	Title
TN2015000285A1 (en)	2016-10-03	Therapeutically active pyrazolo-pyrimidine derivatives
WO2013024291A3 (fr)	2013-04-18	Dérivés de pyrimidine fusionnés à activité thérapeutique
BR112016011484A2 (pt)	2017-08-08	Derivados de imidazopirimidina como moduladores de atividade de tnf
MX370814B (es)	2020-01-08	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
IN2015DN03751A (fr)	2015-10-02
IL229193A0 (en)	2013-12-31	The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases
TN2014000298A1 (en)	2015-12-21	Substituted annulated pyrimidines and triazines, and use thereof
IL237761B (en)	2018-12-31	History of pyrrolo[2,3–d]pyrimidine for the treatment of viral infections and other diseases
PH12016500156A1 (en)	2017-04-10	Selective pi3k delta inhibitors
BR112015010663A8 (pt)	2021-06-22	formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA201890827A1 (ru)	2018-10-31	Конденсированные производные пиразола в качестве ингибиторов киназы
CL2013001464A1 (es)	2013-09-06	Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras.
BR112016029630A2 (pt)	2017-08-22	derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
SG10201803331PA (en)	2018-06-28	Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112016011485A2 (pt)	2017-08-08	Derivados de imidazopiridazina como moduladores de atividade de tnf
MX2019003649A (es)	2019-08-14	Inhibidores selectivos de jak1 novedosos y usos de los mismos.
BR112016029632A2 (pt)	2017-08-22	derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
MX2015014677A (es)	2016-02-19	Formulaciones farmaceuticas, proceso, formas solidas y metodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)pi ridin-3-ii)-3,4-hidropirazino[2,3-b]pirazin-2(1h)-ona.
BR112016029635A2 (pt)	2017-08-22	derivados pirazolo-piridina como inibidores de quinase
UA114825C2 (uk)	2017-08-10	Терапевтично активні похідні піразолопіримідину
EA201891349A1 (ru)	2019-01-31	Производные гексагидропиразинотриазинона в качестве ингибиторов киназы
EA201890826A1 (ru)	2018-10-31	Конденсированные производные пиридина в качестве ингибиторов киназы
ECSP15031293A (es)	2018-07-31	Derivados de pirazolo-pirimidina terapeuticamente activos
IL231934A (en)	2017-03-30	4-Amino-3-Phenylamino-6-Phenylpyrazolo (4,3-d) Pyramidine derivatives, their production and use as active antiviral substances
HK1196600A (en)	2014-12-19	Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases